Physician profile
Cameron Cooper
NPI 1518453976
$1,536.42
in general payments reported to CMS, 2019-2025
23 companies · $388 in 2025
The $388 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $133 · 2022: $87.49 · 2023: $185 · 2024: $742 · 2025: $388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,316.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $296.42 | 2023-2025 | |
| Medtronic, INC. | $207.71 | 2021-2025 | Intellis Adaptivestim, Inceptiv |
| Astrazeneca Pharmaceuticals LP | $191.62 | 2024-2025 | Breztri, Farxiga, Airsupra |
| Kyowa Kirin, INC. | $124.81 | 2024 | Nourianz |
| Amgen INC. | $81.15 | 2023-2024 | Otezla, Repatha |
| Novo Nordisk INC | $70.76 | 2024 | Ozempic, Rybelsus |
| Boston Scientific Corporation | $65.67 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $55.83 | 2021 | |
| Smith+Nephew, INC. | $55.65 | 2022 | |
| Lilly USA, LLC | $46.13 | 2023-2024 | Mounjaro, Trulicity, Zepbound |
| Inspire Medical Systems, INC. | $43.97 | 2024 | Inspire |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.27 | 2025 | Caplyta |
| Baxter Healthcare | $39.81 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Ferring Pharmaceuticals INC. | $36.40 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.77 | 2021-2024 | Trintellix |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $28.87 | 2023-2024 | Quviviq |
| Vertex Pharmaceuticals Incorporated | $28.08 | 2025 | |
| Verity Pharmaceuticals INC. | $18.92 | 2025 | Tlando |
| Astellas Pharma US INC | $18.26 | 2025 | Veozah |
| Pfizer INC. | $15.09 | 2025 | |
| Exact Sciences Corporation | $14.40 | 2025 | Cologuard Collection Kit |
| Supernus Pharmaceuticals, INC. | $13.48 | 2024 | Qelbree |
| Heron Therapeutics, INC. | $12.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cameron Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.